×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NYSE:DGX

Quest Diagnostics (DGX) Stock Forecast, Price & News

$145.39
+3.74 (+2.64%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$141.61
$145.40
50-Day Range
$132.42
$145.39
52-Week Range
$125.77
$174.16
Volume
892,336 shs
Average Volume
1.23 million shs
Market Capitalization
$17.06 billion
P/E Ratio
9.68
Dividend Yield
1.86%
Beta
1.05
30 days | 90 days | 365 days | Advanced Chart
Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Quest Diagnostics logo

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
74834L10
Employees
49,000
Year Founded
1967

Sales & Book Value

Annual Sales
$10.79 billion
Cash Flow
$18.91 per share
Book Value
$54.66 per share

Profitability

Net Income
$2.00 billion
Pretax Margin
22.71%

Debt

Price-To-Earnings

Miscellaneous

Free Float
115,663,000
Market Cap
$17.06 billion
Optionable
Optionable

Company Calendar

Ex-Dividend for 4/20 Dividend
4/05/2022
Dividend Payable
4/20/2022
Last Earnings
4/21/2022
Today
5/28/2022
Ex-Dividend for 7/20 Dividend
7/05/2022
Dividend Payable
7/20/2022
Next Earnings (Estimated)
7/28/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.51 out of 5 stars

Medical Sector

136th out of 1,424 stocks

Medical Laboratories Industry

3rd out of 33 stocks

Analyst Opinion: 1.2Community Rank: 3.5Dividend Strength: 4.2Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

Is Quest Diagnostics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Quest Diagnostics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View analyst ratings for Quest Diagnostics
or view top-rated stocks.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022.
View our earnings forecast for Quest Diagnostics
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) announced its earnings results on Thursday, April, 21st. The medical research company reported $3.22 EPS for the quarter, beating the consensus estimate of $2.91 by $0.31. The medical research company earned $2.61 billion during the quarter, compared to the consensus estimate of $2.64 billion. Quest Diagnostics had a net margin of 17.61% and a trailing twelve-month return on equity of 27.08%. The firm's quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.76 earnings per share.
View Quest Diagnostics' earnings history
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Tuesday, May 17th. Stockholders of record on Wednesday, July 6th will be paid a dividend of $0.66 per share on Wednesday, July 20th. This represents a $2.64 annualized dividend and a yield of 1.82%. The ex-dividend date is Tuesday, July 5th.
View Quest Diagnostics' dividend history
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics pays an annual dividend of $2.64 per share and currently has a dividend yield of 1.86%. Quest Diagnostics has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Quest Diagnostics is 17.58%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 31.88% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.
View Quest Diagnostics' dividend history.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its board has authorized a stock buyback program on Thursday, February 4th 2021, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 6.1% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's leadership believes its shares are undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY22 earnings guidance on Thursday, April, 21st. The company provided earnings per share guidance of $9.00-9.50 for the period, compared to the consensus estimate of $8.98. The company issued revenue guidance of $9.2-9.5 billion, compared to the consensus revenue estimate of $9.35 billion.

What price target have analysts set for DGX?

10 equities research analysts have issued 1 year price objectives for Quest Diagnostics' stock. Their forecasts range from $129.00 to $170.00. On average, they anticipate Quest Diagnostics' share price to reach $150.33 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Quest Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Quest Diagnostics' key executives?
Quest Diagnostics' management team includes the following people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 65, Pay $4.3M)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 60) (LinkedIn Profile)
  • Mr. James E. Davis, Exec. VP & Chief Exec. Officer - Elect (Age 59, Pay $1.44M)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced & Gen. Diagnostics Clinical Solutions (Age 47, Pay $1.31M)
  • Mr. Michael J. Deppe, VP, Corp. Controller & Chief Accounting Officer (Age 55) (LinkedIn Profile)
  • Ms. Gabrielle Wolfson, Sr. VP and Chief Information & Digital Officer
  • Mr. Shawn C. Bevec, VP of Investor Relations
  • Mr. Michael E. Prevoznik, Sr. VP & Gen. Counsel (Age 60) (LinkedIn Profile)
  • Mr. Timothy Sharpe, VP of Compliance
  • Mr. Gary D. Samuels, VP of Corp. Communications
What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics CEO Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among Quest Diagnostics' employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.94%), BlackRock Inc. (10.91%), State Street Corp (5.22%), Victory Capital Management Inc. (2.46%), American Century Companies Inc. (2.24%) and Dimensional Fund Advisors LP (1.87%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Gail R Wilensky, Mark Guinan, Michael E Prevoznik, Michael J Deppe, Stephen H Rusckowski and Stephen H Rusckowski.
View institutional ownership trends for Quest Diagnostics
.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Renaissance Technologies LLC, Massachusetts Financial Services Co. MA, Sumitomo Mitsui Trust Holdings Inc., Lazard Asset Management LLC, Acadian Asset Management LLC, State Street Corp, and JPMorgan Chase & Co.. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Gail R Wilensky, Michael E Prevoznik, and Stephen H Rusckowski.
View insider buying and selling activity for Quest Diagnostics
or view top insider-selling stocks.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Vanguard Group Inc., Victory Capital Management Inc., Pacer Advisors Inc., Allianz Asset Management GmbH, Robeco Institutional Asset Management B.V., and Walleye Trading LLC.
View insider buying and selling activity for Quest Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $145.39.

How much money does Quest Diagnostics make?

Quest Diagnostics has a market capitalization of $17.06 billion and generates $10.79 billion in revenue each year. The medical research company earns $2.00 billion in net income (profit) each year or $15.019990 on an earnings per share basis.

How many employees does Quest Diagnostics have?

Quest Diagnostics employs 49,000 workers across the globe.

Does Quest Diagnostics have any subsidiaries?

The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).

When was Quest Diagnostics founded?

Quest Diagnostics was founded in 1967.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company can be reached via phone at (973) 520-2700, via email at [email protected], or via fax at 201-462-4169.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.